Comparative effects of atorvastatin 80 mg and rosuvastatin 40 mg on the levels of serum endocan, chemerin, and galectin-3 in patients with acute myocardial infarction

Öz:

Objective: Endocan, chemerin, and galectin-3 are discrete biomarkers associated with cardiovascular diseases and acting through different pathophysiological pathways. The aim of this study is to investigate and compare the effects of high doses of atorvastatin and rosuvastatin on serum endocan, chemerin, and galectin-3 levels in patients with acute myocardial infarction (AMI).Methods: Sixty-three patients with AMI were randomized to receive atorvastatin (80 mg/day) or rosuvastatin (40 mg/day) after percutaneous revascularization. Serum levels of endocan, chemerin, and galectin-3 were evaluated at baseline and after 4-week therapy.Results: Endocan levels were not decreased statistically significantly with atorvastatin 80 mg, but rosuvastatin 40 mg markedly decreased the levels of endocan according to baseline [from 110.27 (86.03–143.69) pg/mL to 99.22 (78.30–122.87) pg/mL with atorvastatin 80 mg and from 110.73 (77.28–165.22) pg/mL to 93.40 (70.48–115.13) pg/mL with rosuvastatin 40 mg, p=0.242 for atorvastatin 80 mg and p=0.014 for rosuvastatin 40 mg]. Chemerin levels significantly decreased in both groups according to baseline [from 264.90 (196.00–525.95) ng/mL to 135.00 (105.95–225.65) ng/ mL with atorvastatin 80 mg and from 309.95 (168.87–701.27) ng/mL to 121.25 (86.60–212.65) ng/mL with rosuvastatin 40 mg, p<0.001, respectively, for both groups]. Galectin-3 levels did not change markedly with atorvastatin 80 mg, but they decreased with rosuvastatin 40 mg [from 17.00(13.10–22.25) ng/mL to 19.30 (15.25–23.45) ng/mL with atorvastatin 80 mg, p=0.721, and from 18.25 (12.82–23.82) ng/mL to 16.60 (10.60–20.15) ng/mL with rosuvastatin 40 mg, p=0.074]. There were no significant between-group differences in terms of absolute and percentage changes of endocan, chemerin, and galectin-3 at 4 weeks.Conclusion: We reported that both statins similarly decreased the endocan levels, whereas rosuvastatin seems to have more prominent effects on the reduction of the chemerin and galectin-3 levels in patients with AMI. (Anatol J Cardiol 2019; 22: 240-9)

Anahtar Kelime:

Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık

1. The top 10 causes of death 2017 [cited 2017 07.03.2017]. Available from: URL: http://www.who.int/mediacentre/factsheets/fs310/en/. 2. White HD, Chew DP. Acute myocardial infarction. Lancet 2008; 372: 570-84.
3. Pai JK, Pischon T, Ma J, Manson JE, Hankinson SE, Joshipura K, et al. Inflammatory markers and the risk of coronary heart disease in men and women. N Engl J Med 2004; 351: 2599-610.
4. Boekholdt SM, Hack CE, Sandhu MS, Luben R, Bingham SA, Wareham NJ, et al. C-reactive protein levels and coronary artery disease incidence and mortality in apparently healthy men and women: the EPIC-Norfolk prospective population study 1993-2003. Atherosclerosis 2006; 187: 415-22.
5. Neunteufl T, Katzenschlager R, Hassan A, Klaar U, Schwarzacher S, Glogar D, et al. Systemic endothelial dysfunction is related to the extent and severity of coronary artery disease. Atherosclerosis 1997; 129: 111-8.
6. Menon P, Kocher ON, Aird WC. Endothelial Cell Specific Molecule-1 (ESM-1), a Novel Secreted Proteoglycan Stimulates Vascular Smooth Muscle Cell Proliferation and Migration. Circulation 2011; 124 (Suppl 21): A15455.
7. Scherpereel A, Depontieu F, Grigoriu B, Cavestri M, Tsicopoulos A, Gentina T, et al. Endocan, a new endothelial marker in human sepsis. Crit Care Med 2006; 34: 532-7.
8. Roudnicky F, Poyet C, Wild P, Krampitz S, Negrini F, Huggenberger R, et al. Endocan is upregulated on tumor vessels in invasive bladder cancer where it mediates VEGF-A-induced angiogenesis. Cancer Res 2013; 73: 1097-106.
9. Kose M, Emet S, Akpinar TS, Kocaaga M, Cakmak R, Akarsu M, et al. Serum Endocan Level and the Severity of Coronary Artery Disease: A Pilot Study. Angiology 2015; 66: 727-31.
10. Kundi H, Balun A, Cicekcioglu H, Karayigit O, Topcuoglu C, Kilinckaya MF, et al. Admission Endocan Level may be a Useful Predictor for In-Hospital Mortality and Coronary Severity Index in Patients With ST-Segment Elevation Myocardial Infarction. Angiology 2017; 68: 46-51.
11. Rosen ED, Spiegelman BM. Adipocytes as regulators of energy balance and glucose homeostasis. Nature 2006; 444: 847-53.
12. Bozaoglu K, Bolton K, McMillan J, Zimmet P, Jowett J, Collier G, et al. Chemerin is a novel adipokine associated with obesity and metabolic syndrome. Endocrinology 2007; 148: 4687-94.
13. Goralski KB, McCarthy TC, Hanniman EA, Zabel BA, Butcher EC, Parlee SD, et al. Chemerin, a novel adipokine that regulates adipogenesis and adipocyte metabolism. J Biol Chem 2007; 282: 28175-88.
14. Meric M, Soylu K, Avci B, Yuksel S, Gulel O, Yenercag M, et al. Evaluation of plasma chemerin levels in patients with non-dipper blood pressure patterns. Med Sci Monit 2014; 20: 698-705.
15. Aksan G, İnci S, Nar G, Soylu K, Gedikli Ö, Yüksel S, et al. Association of serum chemerin levels with the severity of coronary artery disease in patients with metabolic syndrome. Int J Clin Exp Med 2014; 7: 5461-8.
16. Xiaotao L, Xiaoxia Z, Yue X, Liye W. Serum chemerin levels are associated with the presence and extent of coronary artery disease. Coron Artery Dis 2012; 23: 412-6.
17. Ji Q, Lin Y, Liang Z, Yu K, Liu Y, Fang Z, et al. Chemerin is a novel biomarker of acute coronary syndrome but not of stable angina pectoris. Cardiovasc Diabetol 2014; 13: 145.
18. Sharma UC, Pokharel S, van Brakel TJ, van Berlo JH, Cleutjens JPM, Schroen B, et al. Galectin-3 marks activated macrophages in failure-prone hypertrophied hearts and contributes to cardiac dysfunction. Circulation 2004; 110: 3121-8.
19. Henderson NC, Mackinnon AC, Farnworth SL, Kipari T, Haslett C, Iredale JP, et al. Galectin-3 expression and secretion links macrophages to the promotion of renal fibrosis. Am J Pathol 2008; 172: 288-98.
20. Raimond J, Zimonjic DB, Mignon C, Mattei MG, Popescu NC, Monsigny M, et al. Mapping of the galectin-3 gene (LGALS3) to human Chromosome 14 at region 14q21-22. Mamm Genome 1997; 8: 706-7.
21. Imran TF, Shin HJ, Mathenge N, Wang F, Kim B, Joseph J, et al. MetaAnalysis of the Usefulness of Plasma Galectin-3 to Predict the Risk of Mortality in Patients With Heart Failure and in the General Population. Am J Cardiol 2017; 119: 57-64.
22. Catapano AL, Graham I, De Backer G, Wiklund O, Chapman MJ, Drexel H, et al. 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias The Task Force for the Management of Dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS) Developed with the special contribution of the European Assocciation for Cardiovascular Prevention & Rehabilitation (EACPR). Atherosclerosis 2016; 253: 281-344.
23. Altunkeser BB, Tuncez A, Ozturk B, Tezcan H, Ates MS, Yilmaz C, et al. Comparative effects of high-dose atorvastatin versus rosuvastatin on lipid parameters, oxidized low-density lipoprotein, and proprotein convertase subtilisin kexin 9 in acute coronary syndrome. Coron Artery Dis 2019; 30: 285-90.
24. Thygesen K, Alpert JS, Jaffe AS, Simoons ML, Chaitman BR, White HD, et al. Third Universal Definition of Myocardial Infarction. Circulation 2012; 126: 2020-35.
25. Amsterdam EA, Wenger NK, Brindis RG, Casey DE, Ganiats TG, Holmes DR Jr, et al. 2014 AHA/ACC Guideline for the Management of Patients With Non-ST-Elevation Acute Coronary Syndromes: Executive Summary A Report of the American College of Cardiology/ American Heart Association Task Force on Practice Guidelines. Circulation 2014; 130: 2354-94.
26. Weng TC, Yang YH, Lin SJ, Tai SH. A systematic review and metaanalysis on the therapeutic equivalence of statins. J Clin Pharm Ther 2010; 35: 139-51.
27. LaRosa JC, Grundy SM, Waters DD, Shear C, Barter P, Fruchart JC, et al.; Treating to New Targets (TNT) Investigators. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 2005; 352: 1425-35.
28. Nissen SE, Nicholls SJ, Sipahi I, Libby P, Raichlen JS, Ballantyne CM, et al.; ASTEROID Investigators. Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial. JAMA 2006; 295: 1556-65.
29. Pitt B, Loscalzo J, Monyak J, Miller E, Raichlen J. Comparison of lipid-modifying efficacy of rosuvastatin versus atorvastatin in patients with acute coronary syndrome (from the LUNAR study). Am J Cardiol 2012; 109: 1239-46.
30. Balta S, Mikhailidis DP, Demirkol S, Ozturk C, Celik T, Iyisoy A. Endocan: A novel inflammatory indicator in cardiovascular disease? Atherosclerosis 2015; 243: 339-43.
31. Balta S, Mikhailidis DP, Demirkol S, Ozturk C, Kurtoglu E, Demir M, et al. Endocan--a novel inflammatory indicator in newly diagnosed patients with hypertension: a pilot study. Angiology 2014; 65: 773-7.
32. Qiu CR, Fu Q, Sui J, Zhang Q, Wei P, Wu Y, et al. Serum Endothelial Cell-Specific Molecule 1 (Endocan) Levels in Patients With Acute Myocardial Infarction and Its Clinical Significance. Angiology 2017; 68: 354-9.
33. Xiong C, Zhao ZW, Chen ZY, Wu LZ, Luo YK, Hu FD, et al. Elevated Human Endothelial Cell-Specific Molecule-1 Level and Its Association With Coronary Artery Disease in Patients With Hypertension. J Invest Med 2015; 63: 867-70.
34. Almuti K, Rimawi R, Spevack D, Ostfeld RJ. Effects of statins beyond lipid lowering: potential for clinical benefits. Int J Cardiol 2006; 109: 7-15.
35. Packard CJ, Shepherd J, Cobbe SM, Ford I, Isles CG, McKillop JH, et al. Influence of pravastatin and plasma lipids on clinical events in the West of Scotland Coronary Prevention Study (WOSCOPS). Circulation 1998; 97: 1440-5.
36. Nissen SE, Tuzcu EM, Schoenhagen P, Crowe T, Sasiela WJ, Tsai J, et al.; Reversal of Atherosclerosis with Aggressive Lipid Lowering (REVERSAL) Investigators. Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease. N Engl J Med 2005; 352: 29-38.
37. Rikitake Y, Kawashima S, Takeshita S, Yamashita T, Azumi H, Yasuhara M, et al. Anti-oxidative properties of fluvastatin, an HMG-CoA reductase inhibitor, contribute to prevention of atherosclerosis in cholesterol-fed rabbits. Atherosclerosis 2001; 154: 87-96.
38. Williams JK, Sukhova GK, Herrington DM, Libby P. Pravastatin has cholesterol-lowering independent effects on the artery wall of atherosclerotic monkeys. J Am Coll Cardiol 1998; 31: 684-91.
39. Laufs U, La Fata V, Plutzky J, Liao JK. Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors. Circulation 1998; 97: 1129-35.
40. Xiong W, Luo Y, Wu L, Liu F, Liu H, Li J, et al. Chemerin Stimulates Vascular Smooth Muscle Cell Proliferation and Carotid Neointimal Hyperplasia by Activating Mitogen-Activated Protein Kinase Signaling. PLoS One 2016; 11: e0165305.
41. Krysiak R, Zmuda W, Okopien B. The effect of simvastatin-ezetimibe combination therapy on adipose tissue hormones and systemic inflammation in patients with isolated hypercholesterolemia. Cardiovasc Ther 2014; 32: 40-6.
42. Sahebkar A, Giua R, Pedone C. Impact of statin therapy on plasma leptin concentrations: a systematic review and meta-analysis of randomized placebo-controlled trials. Br J Clin Pharmacol 2016; 82: 1674-84.
43. Ho JE, Liu CY, Lyass A, Courchesne P, Pencina MJ, Vasan RS, et al. Galectin-3, a Marker of Cardiac Fibrosis, Predicts Incident Heart Failure in the Community. J Am Coll Cardiol 2012; 60: 1249-56.
44. Madrigal-Matute J, Lindholt JS, Fernandez-Garcia CE, BenitoMartin A, Burillo E, Zalba G, et al. Galectin-3, a biomarker linking oxidative stress and inflammation with the clinical outcomes of patients with atherothrombosis. J Am Heart Assoc 2014; 3. pii: e000785.
45. Winter MP, Wiesbauer F, Alimohammadi A, Blessberger H, Pavo N, Schillinger M, et al. Soluble galectin-3 is associated with premature myocardial infarction. Eur J Clin Invest 2016; 46: 386-91.
46. MacKinnon AC, Liu XJ, Hadoke PWF, Miller MR, Newby DE, Sethi T. Inhibition of galectin-3 reduces atherosclerosis in apolipoprotein E-deficient mice. Glycobiology 2013; 23: 654-63.
47. Chang YY, Wu YW, Lee JK, Lin YM, Lin YT, Kao HL, et al. Effects of 12 weeks of atorvastatin therapy on myocardial fibrosis and circulating fibrosis biomarkers in statin-naive patients with hypertension with atherosclerosis. J Investig Med 2016; 64: 1194-9.
48. Gullestad L, Ueland T, Kjekshus J, Nymo SH, Hulthe J, Muntendam P, et al.; CORONA Study Group. Galectin-3 predicts response to statin therapy in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA). Eur Heart J 2012; 33: 2290-6.

APA	Tunçez A, ALTUNKESER B, ÖZTÜRK B, ateş m, TEZCAN H, AYDOĞAN C, Kırık E, Yalcin U, AYGÜL N, Demir K, Akyurek F (2019). Comparative effects of atorvastatin 80 mg and rosuvastatin 40 mg on the levels of serum endocan, chemerin, and galectin-3 in patients with acute myocardial infarction. , 240 - 249. 10.14744/AnatolJCardiol.2019.64249
Chicago	Tunçez Abdullah,ALTUNKESER Bülent Behlül,ÖZTÜRK Bahadır,ateş muhammet salih,TEZCAN HÜSEYİN,AYDOĞAN Canan,Kırık Emre Can,Yalcin Ulvi,AYGÜL Nazif,Demir Kenan,Akyurek Fikret Comparative effects of atorvastatin 80 mg and rosuvastatin 40 mg on the levels of serum endocan, chemerin, and galectin-3 in patients with acute myocardial infarction. (2019): 240 - 249. 10.14744/AnatolJCardiol.2019.64249
MLA	Tunçez Abdullah,ALTUNKESER Bülent Behlül,ÖZTÜRK Bahadır,ateş muhammet salih,TEZCAN HÜSEYİN,AYDOĞAN Canan,Kırık Emre Can,Yalcin Ulvi,AYGÜL Nazif,Demir Kenan,Akyurek Fikret Comparative effects of atorvastatin 80 mg and rosuvastatin 40 mg on the levels of serum endocan, chemerin, and galectin-3 in patients with acute myocardial infarction. , 2019, ss.240 - 249. 10.14744/AnatolJCardiol.2019.64249
AMA	Tunçez A,ALTUNKESER B,ÖZTÜRK B,ateş m,TEZCAN H,AYDOĞAN C,Kırık E,Yalcin U,AYGÜL N,Demir K,Akyurek F Comparative effects of atorvastatin 80 mg and rosuvastatin 40 mg on the levels of serum endocan, chemerin, and galectin-3 in patients with acute myocardial infarction. . 2019; 240 - 249. 10.14744/AnatolJCardiol.2019.64249
Vancouver	Tunçez A,ALTUNKESER B,ÖZTÜRK B,ateş m,TEZCAN H,AYDOĞAN C,Kırık E,Yalcin U,AYGÜL N,Demir K,Akyurek F Comparative effects of atorvastatin 80 mg and rosuvastatin 40 mg on the levels of serum endocan, chemerin, and galectin-3 in patients with acute myocardial infarction. . 2019; 240 - 249. 10.14744/AnatolJCardiol.2019.64249
IEEE	Tunçez A,ALTUNKESER B,ÖZTÜRK B,ateş m,TEZCAN H,AYDOĞAN C,Kırık E,Yalcin U,AYGÜL N,Demir K,Akyurek F "Comparative effects of atorvastatin 80 mg and rosuvastatin 40 mg on the levels of serum endocan, chemerin, and galectin-3 in patients with acute myocardial infarction." , ss.240 - 249, 2019. 10.14744/AnatolJCardiol.2019.64249
ISNAD	Tunçez, Abdullah vd. "Comparative effects of atorvastatin 80 mg and rosuvastatin 40 mg on the levels of serum endocan, chemerin, and galectin-3 in patients with acute myocardial infarction". (2019), 240-249. https://doi.org/10.14744/AnatolJCardiol.2019.64249

APA	Tunçez A, ALTUNKESER B, ÖZTÜRK B, ateş m, TEZCAN H, AYDOĞAN C, Kırık E, Yalcin U, AYGÜL N, Demir K, Akyurek F (2019). Comparative effects of atorvastatin 80 mg and rosuvastatin 40 mg on the levels of serum endocan, chemerin, and galectin-3 in patients with acute myocardial infarction. The Anatolian Journal of Cardiology, 22(5), 240 - 249. 10.14744/AnatolJCardiol.2019.64249
Chicago	Tunçez Abdullah,ALTUNKESER Bülent Behlül,ÖZTÜRK Bahadır,ateş muhammet salih,TEZCAN HÜSEYİN,AYDOĞAN Canan,Kırık Emre Can,Yalcin Ulvi,AYGÜL Nazif,Demir Kenan,Akyurek Fikret Comparative effects of atorvastatin 80 mg and rosuvastatin 40 mg on the levels of serum endocan, chemerin, and galectin-3 in patients with acute myocardial infarction. The Anatolian Journal of Cardiology 22, no.5 (2019): 240 - 249. 10.14744/AnatolJCardiol.2019.64249
MLA	Tunçez Abdullah,ALTUNKESER Bülent Behlül,ÖZTÜRK Bahadır,ateş muhammet salih,TEZCAN HÜSEYİN,AYDOĞAN Canan,Kırık Emre Can,Yalcin Ulvi,AYGÜL Nazif,Demir Kenan,Akyurek Fikret Comparative effects of atorvastatin 80 mg and rosuvastatin 40 mg on the levels of serum endocan, chemerin, and galectin-3 in patients with acute myocardial infarction. The Anatolian Journal of Cardiology, vol.22, no.5, 2019, ss.240 - 249. 10.14744/AnatolJCardiol.2019.64249
AMA	Tunçez A,ALTUNKESER B,ÖZTÜRK B,ateş m,TEZCAN H,AYDOĞAN C,Kırık E,Yalcin U,AYGÜL N,Demir K,Akyurek F Comparative effects of atorvastatin 80 mg and rosuvastatin 40 mg on the levels of serum endocan, chemerin, and galectin-3 in patients with acute myocardial infarction. The Anatolian Journal of Cardiology. 2019; 22(5): 240 - 249. 10.14744/AnatolJCardiol.2019.64249
Vancouver	Tunçez A,ALTUNKESER B,ÖZTÜRK B,ateş m,TEZCAN H,AYDOĞAN C,Kırık E,Yalcin U,AYGÜL N,Demir K,Akyurek F Comparative effects of atorvastatin 80 mg and rosuvastatin 40 mg on the levels of serum endocan, chemerin, and galectin-3 in patients with acute myocardial infarction. The Anatolian Journal of Cardiology. 2019; 22(5): 240 - 249. 10.14744/AnatolJCardiol.2019.64249
IEEE	Tunçez A,ALTUNKESER B,ÖZTÜRK B,ateş m,TEZCAN H,AYDOĞAN C,Kırık E,Yalcin U,AYGÜL N,Demir K,Akyurek F "Comparative effects of atorvastatin 80 mg and rosuvastatin 40 mg on the levels of serum endocan, chemerin, and galectin-3 in patients with acute myocardial infarction." The Anatolian Journal of Cardiology, 22, ss.240 - 249, 2019. 10.14744/AnatolJCardiol.2019.64249
ISNAD	Tunçez, Abdullah vd. "Comparative effects of atorvastatin 80 mg and rosuvastatin 40 mg on the levels of serum endocan, chemerin, and galectin-3 in patients with acute myocardial infarction". The Anatolian Journal of Cardiology 22/5 (2019), 240-249. https://doi.org/10.14744/AnatolJCardiol.2019.64249